Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

• Status: Recruiting
• Trial end date: 2026-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: Cetuximab; Fluorouracil; Formyltetrahydrofolates; Irinotecan; Oxaliplatin

Criteria

Inclusion Criteria:

• Age 18 ~ 75 years old, regardless of gender

• Patients with colorectal cancer diagnosed by histopathology or cytology

• Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy

• Having at least one assessable tumor focus

• ECoG physical condition score ≤ 2 points

• Voluntarily participate and sign informed consent

Exclusion Criteria:

• Patients diagnosed with metastasis

• Patients who cannot obtain tumor samples

• Pregnant and lactating women

• Patients with poor compliance

• Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment

• Patients with other malignant tumors

• Suffering from serious mental and nervous system diseases

• The researchers believe that patients should not be selected for this study